Analysis:
(a) Source analysis  
1. “=== STOCK RETURN DISTRIBUTION ===” block (programmatic back-test on PFE, 2000-2026).  
   • Factual, reproducible, time-stamped. Gives unconditional and single-factor conditional win-rates for exactly the 9-trading-day horizon we need. Highest-quality quantitative anchor.  
2. Yahoo Finance quote page (Mar 1–2 2026 snapshot).  
   • Factual price/volume data; qualitative news blurbs without author attribution. Useful mainly for today’s reference close ($27.65) and confirmation that price is near its 52-week high.  
3. Morningstar profile (27 Feb 2026).  
   • Audited fundamental data; no near-term catalyst for the next 9 sessions. Low weight for outside view.  
4. Intellectia.ai technical‐signal article (Mar 2 2026).  
   • Model-generated “Strong Buy” rating; unknown methodology, no track record. Treated as opinion with low evidentiary weight.  
5. Seasonality / Deloitte / L.E.K. / Macro S&P-500 pieces.  
   • Either long-term or index-level studies; not specific to the narrow 9-day window. Informational value for this forecast ≈ 0.  
6. Agent report on missing joint conditional probability.  
   • Correctly flags data gap; confirms we must interpolate between available single-factor conditionals.

(b) Reference class analysis  
Candidates:  
1. All 9-trading-day PFE windows since 2000 → N = 2,506.  
2. Same, filtered by “price in top decile of 52-wk range”.  
3. Same, filtered by “positive prior 5-day return”.  
Because our horizon (9 trading days) and subject (PFE) match class 1 perfectly, class 1 is the primary reference class. Classes 2 & 3 are useful secondary lenses.

(c) Time-frame analysis  
• Horizon: 9 NYSE sessions (Mon Mar 2 → Fri Mar 13 2026).  
• Historical unconditional P(up) over 9-day windows: 52.4 %.  
• Std-dev of 9-day returns: 4.4 %. A one-day move of ≈ ±$1.20 would flip the outcome; such moves are routine (∼27 ¢ σ per day).  
• Current context signals:  
  – Price in top decile of 52-wk range (bullish; conditional P = 58.3 %).  
  – Prior 5-day return +3.8 % (mildly bullish; conditional P = 53.8 %).  
  – 30-day realised vol above median (bearish; conditional P = 47.9 %).  
No earnings release or known binary catalyst is scheduled before Mar 13 (next earnings Apr 28).

(d) Justification  
Start from 52.4 % base rate.  
Adjustments (using historical deltas):  
+5.9 pp for “top‐decile” signal → 58.3 %  
+1.4 pp for “positive 5-day momentum” → 59.7 %  
−4.5 pp for “volatility above median” → 55.2 %  
Correlation among filters means the arithmetic sum over-counts; history shows momentum and high-price signals often co-occur. Conservatively halve the net adjustment (+2.8 pp) relative to base:  
52.4 % + 2.8 pp ≈ 55.2 %.  
Round a bit downward for model uncertainty (missing exact joint statistic, 9-day sample still limited) → 53 – 55 % seems most defensible.

Outside view calibration:
• Anchor: 52.4 % unconditional.  
• Directional evidence slightly bullish but weak; historical surprises (drug-data headlines, macro shocks) happen ≈ 1 in 20 windows and can easily reverse a ­2-4 % daily move.  
• Expert/market consensus: Analysts’ 1-yr target ($28.43) is only 3 % above today—neutral for a 9-day view.  
Given typical upset frequency and our modest positive tilt, shrink toward 50 % by ~2 pp.

Outside View Prediction:
53.0 %